Adocia goes it alone as Lilly ends insulin analog deal
This article was originally published in Scrip
Executive Summary
French biotech Adocia has decided to brave theworld of diabetes alone after Lilly returned the rights to the company's BioChaperone technology for the formulation of fast-acting insulin analog.